本態性血小板血症(Essential Thrombocythemia)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Essential Thrombocythemia Overview 7
Therapeutics Development 8
Pipeline Products for Essential Thrombocythemia – Overview 8
Pipeline Products for Essential Thrombocythemia – Comparative Analysis 9
Essential Thrombocythemia – Therapeutics under Development by Companies 10
Essential Thrombocythemia – Therapeutics under Investigation by Universities/Institutes 11
Essential Thrombocythemia – Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Essential Thrombocythemia – Products under Development by Companies 15
Essential Thrombocythemia – Products under Investigation by Universities/Institutes 16
Essential Thrombocythemia – Companies Involved in Therapeutics Development 17
Aop Orphan Pharmaceuticals AG 17
Biogenomics Limited 18
Galena Biopharma, Inc. 19
Gilead Sciences, Inc. 20
Incyte Corporation 21
Italfarmaco S.p.A. 22
Novartis AG 23
Onconova Therapeutics, Inc. 24
PharmaEssentia Corporation 25
Essential Thrombocythemia – Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
anagrelide hydrochloride CR – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
anagrelide hydrochloride PR – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
erismodegib – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
givinostat – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
interferon alfa-2b (recombinant) – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
momelotinib – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
peginterferon alfa-2b – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
rigosertib sodium – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ruxolitinib phosphate – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Molecules to Inhibit JAK for Oncology and Hematological Disorders – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Essential Thrombocythemia – Recent Pipeline Updates 58
Essential Thrombocythemia – Dormant Projects 78
Essential Thrombocythemia – Discontinued Products 79
Essential Thrombocythemia – Product Development Milestones 80
Featured News & Press Releases 80
Nov 18, 2014: Galena Biopharma Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial 80
Feb 13, 2013: Novartis’s Myelofibrosis Drug Jakavi Turned Down By NICE In Draft Guidance 80
May 31, 2011: YM BioSciences Announces Orphan Drug Designation For JAK1/JAK2 Inhibitor CYT387 In Europe 81
Dec 06, 2010: Incyte Presents Positive Phase II Trial Results Of INCB18424 In Advanced Polycythemia Vera And Essential Thrombocythemia At ASH Annual Meeting 82
May 28, 2009: Incyte Provides Update on Special Protocol Assessment for INCB18424 As A New Treatment for Myelofibrosis 83
Appendix 84
Methodology 84
Coverage 84
Secondary Research 84
Primary Research 84
Expert Panel Validation 84
Contact Us 84
Disclaimer 85